Merckâs Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIAÂ® (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy